Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01868724 · ClinicalTrials.gov registry record
Identification and Validation of Biomarkers of Acute Kidney Injury Recovery
A clinical trial, sponsored by Astute Medical.
- Completed
- Registry status
- 362
- Enrollment target
NCT01868724: Completed study, sponsored by Astute Medical.
NCT01868724 is a clinical trial that has completed, run by Astute Medical. The registered enrollment target is 362 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01868724 has completed, sponsored by Astute Medical.
- COMPLETED
- Registry status
- 362 participants
- Enrollment target
Study Summary
This study is to collect blood and urine samples to help identify and validate protein biomarkers of recovery from moderate or severe acute kidney injury (AKI).
Primary Outcome
This study is a multi-center study intended to enroll enough subjects to validate biomarkers for acute kidney injury recovery. Subjects enrolled will be those with known moderate to severe AKI. The study is to determine the outcome of Major Adverse Kidney Event (MAKE) and Major Adverse Cardiac Event (MACE) during a period of up to 7 days.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-09 |
What the finished NCT01868724 record still lists
NCT01868724 is an observational study that tracks outcomes without assigning an intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01868724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01868724 about?
NCT01868724 is a clinical study titled "Identification and Validation of Biomarkers of Acute Kidney Injury Recovery". This study is to collect blood and urine samples to help identify and validate protein biomarkers of recovery from moderate or severe acute kidney injury (AKI).
What is the current status of trial NCT01868724?
This trial is currently completed. The enrollment target is 362 participants. The study started on 2013-06. Estimated completion is 2014-09.
Who is sponsoring clinical trial NCT01868724?
This trial is sponsored by Astute Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04988555 · 362 participants · Phase 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
- NCT05536141 · 362 participants · Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- NCT06534983 · 362 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
- NCT06472245 · 363 participants · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia